180 Life Sciences CORP Schedule 13D activist filings

ETHZilla Corporation settled disputes with Elray Resources and Luxor Capital, agreeing to repurchase 1.318 million shares for $1 million, while Elray exercised warrants and subsequently sold shares.

Blair Jordan's beneficial ownership in 180 Life Sciences Corp. has fallen below 5% following new option grants and accelerated vesting of restricted stock.

Blair Jordan, CEO of 180 Life Sciences Corp., has updated his beneficial ownership to 31.3% of common stock, reflecting adjustments to restricted stock grants and new option awards, as detailed in an amended Schedule 13D filing.

Blair Jordan, CEO of 180 Life Sciences Corp., has significantly increased his beneficial ownership to 31.7% through accelerated restricted stock vesting, new option and restricted stock grants, and strategic voting agreements.

Blair Jordan, CEO of 180 Life Sciences Corp., has significantly increased his beneficial ownership to 30.2% of the company's common stock through a combination of restricted stock grants and new voting agreements with key shareholders.

Elray Resources, Inc., a significant shareholder in 180 Life Sciences Corp., converted 1 million shares of Series B Convertible Preferred Stock into 1.318 million common shares, increasing its beneficial ownership to 52.8% of the company's outstanding common stock.

Blair Jordan, CEO of 180 Life Sciences Corp., has significantly increased his beneficial ownership in the company to 10.5% through new voting agreements and a restricted stock grant, as detailed in a recent Schedule 13D filing.

Anthony Brian Goodman and Elray Resources, Inc. have disclosed a 57.6% beneficial ownership stake in 180 Life Sciences Corp. following the sale of blockchain casino intellectual property in exchange for convertible preferred stock and warrants.